These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 24313741

  • 1. Tubulin inhibitors: a patent review.
    Liu YM, Chen HL, Lee HY, Liou JP.
    Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
    [Abstract] [Full Text] [Related]

  • 2. [Progress in the study of tubulin inhibitors].
    Shang H, Pan L, Yang S, Chen H, Cheng MS.
    Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
    [Abstract] [Full Text] [Related]

  • 3. Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018).
    Haider K, Rahaman S, Yar MS, Kamal A.
    Expert Opin Ther Pat; 2019 Aug; 29(8):623-641. PubMed ID: 31353978
    [Abstract] [Full Text] [Related]

  • 4. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD, Kumar D, Krishna KV, Kantevari S.
    Curr Top Med Chem; 2017 Aug; 17(22):2523-2537. PubMed ID: 28056738
    [Abstract] [Full Text] [Related]

  • 5. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
    Field JJ, Kanakkanthara A, Miller JH.
    Bioorg Med Chem; 2014 Sep 15; 22(18):5050-9. PubMed ID: 24650703
    [Abstract] [Full Text] [Related]

  • 6. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA, Ducki S, Hirst N, McGown AT.
    Prog Cell Cycle Res; 2003 Sep 15; 5():309-25. PubMed ID: 14593726
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
    Fürst R, Vollmar AM.
    Pharmazie; 2013 Jul 15; 68(7):478-83. PubMed ID: 23923626
    [Abstract] [Full Text] [Related]

  • 10. Identification of novel and potent small-molecule inhibitors of tubulin with antitumor activities by virtual screening and biological evaluations.
    Liu G, Jiao Y, Huang C, Chang P.
    J Comput Aided Mol Des; 2019 Jul 15; 33(7):659-664. PubMed ID: 31165955
    [Abstract] [Full Text] [Related]

  • 11. Microtubule alterations and resistance to tubulin-binding agents (review).
    Drukman S, Kavallaris M.
    Int J Oncol; 2002 Sep 15; 21(3):621-8. PubMed ID: 12168109
    [Abstract] [Full Text] [Related]

  • 12. Microtubules: a dynamic target in cancer therapy.
    Pasquier E, Kavallaris M.
    IUBMB Life; 2008 Mar 15; 60(3):165-70. PubMed ID: 18380008
    [Abstract] [Full Text] [Related]

  • 13. Induction of apoptosis through tubulin inhibition in human cancer cells by new chromene-based chalcones.
    Aryapour H, Riazi GH, Ahmadian S, Foroumadi A, Mahdavi M, Emami S.
    Pharm Biol; 2012 Dec 15; 50(12):1551-60. PubMed ID: 22984888
    [Abstract] [Full Text] [Related]

  • 14. Early investigational tubulin inhibitors as novel cancer therapeutics.
    Nepali K, Ojha R, Lee HY, Liou JP.
    Expert Opin Investig Drugs; 2016 Aug 15; 25(8):917-36. PubMed ID: 27186892
    [Abstract] [Full Text] [Related]

  • 15. Update on tubulin-binding agents.
    Attard G, Greystoke A, Kaye S, De Bono J.
    Pathol Biol (Paris); 2006 Mar 15; 54(2):72-84. PubMed ID: 16545633
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Synthesis and biological evaluation of novel pyranochalcone derivatives as a new class of microtubule stabilizing agents.
    Cao D, Han X, Wang G, Yang Z, Peng F, Ma L, Zhang R, Ye H, Tang M, Wu W, Lei K, Wen J, Chen J, Qiu J, Liang X, Ran Y, Sang Y, Xiang M, Peng A, Chen L.
    Eur J Med Chem; 2013 Apr 15; 62():579-89. PubMed ID: 23425970
    [Abstract] [Full Text] [Related]

  • 19. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
    Coluccia A, Sabbadin D, Brancale A.
    Eur J Med Chem; 2011 Aug 15; 46(8):3519-25. PubMed ID: 21621885
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors.
    Ouyang X, Chen X, Piatnitski EL, Kiselyov AS, He HY, Mao Y, Pattaropong V, Yu Y, Kim KH, Kincaid J, Smith L, Wong WC, Lee SP, Milligan DL, Malikzay A, Fleming J, Gerlak J, Deevi D, Doody JF, Chiang HH, Patel SN, Wang Y, Rolser RL, Kussie P, Labelle M, Tuma MC.
    Bioorg Med Chem Lett; 2005 Dec 01; 15(23):5154-9. PubMed ID: 16198562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.